Journal of Clinical Pathology 1997;50:168-170; doi:10.1136/jcp.50.2.168
Copyright © 1997 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.
Leu-M1 immunoreactivity and phaeochromocytoma.
L Masmiquel,
M Castro-Forns,
I de Torres,
A García,
M T Vidal,
R Simó
Department of Endocrinology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
The aim was to evaluate Leu-M1 immunoreactivity as a prognostic factor in phaeochromocytoma. Anti-Leu-M1 monoclonal antibodies were used to determine the Leu-M1 immunoreactivity in 17 histologically confirmed phaeochromocytomas from 15 patients, using an avidin-biotin technique. Ten patients had a sporadic phaeochromocytoma, and five had multiple endocrine neoplasia type 2A (MEN 2A). Malignancy was diagnosed in three patients by the presence of metastases. Leu-M1 immunoreactivity was shown in 12 (70.5%) phaeochromocytomas. Three patterns of arrangement were observed: isolated (scattered positive cells) (n = 3); focal (aggregates of positive cells) (n = 5), and diffuse patterns (dispersed positive cells) (n = 4). Two cases of malignant phaeochromocytoma were positive (one focal and one isolated pattern). All cases of MEN 2A showed immunoreactivity, although no characteristic pattern was prevalent. A diffuse pattern was observed in all phaeochromocytomas longer than 7 cm. In conclusion, Leu-M1 expression is frequent in phaeochromocytoma. However, Leu-M1 immunoreactivity seems to be useless in predicting malignant behaviour and to be influenced mainly by tumour size.
Terms and conditions relating to subscriptions purchased online ¦ Website terms and conditions ¦ Privacy policy
Copyright © 1997 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.